Trial Profile
Real Life Treatment Regimen of Remicade (Infliximab) in Austria, Monitored Over 5 Years in Plaque Psoriasis Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 01 Sep 2011 Actual end date (June 2010) added as reported by ClinicalTrials.gov.
- 01 Sep 2011 Primary endpoint identified as therapy assessment as reported by ClinicalTrials.gov.
- 12 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.